ArticleFrontiers in pharmacology2026
Gastrodin alleviates mild cognitive impairment and Alzheimer's disease via candidate targeting of ACHE, S1PR5, SERPINE1, and TOP2A: an integrative computational and cellular study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) and its prodromal mild cognitive impairment (MCI) lack effective disease-modifying therapeutic strategies. Gastrodin (GAS), the major bioactive compound of Methods/results: This study adopted an integrated approach of network pharmacology, transcriptome-based machine learning, molecular simulation, and Conclusion: This study identifies four novel candidate core therapeutic targets of GAS against AD/MCI and provides computational evidence for their stable atomic-level binding characteristics. GAS exerts prominent neuroprotective effects through anti-apoptotic and antioxidant mechanisms in Aβ-injured neurons. These findings provide a novel theoretical basis and preclinical evidence for the development of GAS as a natural candidate agent for AD intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.